Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
1.
Orphanet J Rare Dis ; 17(1): 193, 2022 05 12.
Artículo en Inglés | MEDLINE | ID: mdl-35550173

RESUMEN

BACKGROUND: Lysosomal acid lipase deficiency (LALD) is an ultra-rare, inherited metabolic disease within the category of lysosomal storage disorders, affecting an infant's ability to metabolise cholesterol. Developments in treatment, including Enzyme Replacement Therapy, have proven successful, with some children living for a number of years with treatment, although the future still remains unknown. The aim of this study was to explore the lived experiences of parents of children with LALD. MAIN TEXT: Participants were recruited from across the United Kingdom between 2020 and 2021. Eight parents (five mothers and three fathers) whose child had a confirmed diagnosis of LALD were interviewed. Data collected from the semi-structured interviews were audio-record, transcribed and analysed using Interpretative Phenomenological Analysis (IPA). Three superordinate and nine subordinate themes emerged from the data: (1) Uncertainty-a double-edged sword (plunged into an uncertain world, living life with worry and walking the tightrope of stability), (2) Powerless against a shared battle with LALD (a helpless parent, a joint battle, protection against distress and a vulnerable parent needing help) and 3) Accepting a life with LALD (coming to terms with a diagnosis of LALD and a hidden condition). CONCLUSIONS: The findings of this study highlight that the diagnosis of LALD proves to be a very challenging and emotionally distressing time in parents' lives, with increased uncertainty about what the future will hold for their child. This study signified the importance of healthcare pathways and service provisions to support parents and their children throughout diagnosis and beyond.


Asunto(s)
Enfermedad de Wolman , Niño , Terapia de Reemplazo Enzimático , Femenino , Humanos , Lactante , Madres , Padres/psicología , Investigación Cualitativa , Enfermedad de Wolman/diagnóstico , Enfermedad de Wolman
2.
Mol Genet Metab ; 129(2): 98-105, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-31383595

RESUMEN

The outcome of 110 patients with paediatric onset mucopolysaccharidosis II (MPS II) since the commercial introduction of enzyme replacement therapy (ERT) in England in 2007 is reported. Median length of follow up was 10 years 3 months (range = 1 y 2 m to 18 years 6 month). 78 patients were treated with ERT, 18 had no ERT or disease modifying treatment 7 had haematopoietic stem cell transplant, 4 experimental intrathecal therapy and 3 were lost to follow up. There is clear evidence of improved survival (median age of death of ERT treated (n = 16) = 15.13 years (range = 9.53 to 20.58 y), and untreated (n = 17) = 11.43 y (0.5 to 19.13 y) p = .0005). Early introduction of ERT improved respiratory outcome at 16 years, the median FVC (% predicted) of those in whom ERT initiated <8 years = 69% (range = 34-86%) and 48% (25-108) (p = .045) in those started >8 years. However, ERT appears to have minimal impact on hearing, carpal tunnel syndrome or progression of cardiac valvular disease. Cardiac valvular disease occurred in 18/46 (40%), with progression occurring most frequently in the aortic valve 13/46 (28%). The lack of requirement for neurosurgical intervention in the first 8 years of life suggests that targeted imaging based on clinical symptomology would be safe in this age group after baseline assessments. There is also emerging evidence that the neurological phenotype is more nuanced than the previously recognized dichotomy of severe and attenuated phenotypes in patients presenting in early childhood.


Asunto(s)
Terapia de Reemplazo Enzimático , Mucopolisacaridosis II/tratamiento farmacológico , Adolescente , Niño , Preescolar , Recolección de Datos , Progresión de la Enfermedad , Inglaterra , Estudios de Seguimiento , Humanos , Lactante , Mucopolisacaridosis II/mortalidad , Fenotipo , Estudios Retrospectivos , Factores de Tiempo , Resultado del Tratamiento
3.
JIMD Rep ; 44: 79-84, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30097991

RESUMEN

Lathosterolosis is a rare defect of cholesterol synthesis. Only four previous cases have been reported, two of whom were siblings. We report a fifth patient, with a relatively mild phenotype. He presented at 5 years of age with bilateral posterior cataracts, which were managed with lensectomies and intraocular lens implants. He also had learning difficulties, with a full-scale IQ of 64 at 11 years of age. His head circumference is between the 0.4th and 2nd centiles, and he has mild hypotonia and subtle dysmorphism (a high-arched palate, anteverted nostrils, long philtrum and clinodactyly of toes). The diagnosis was established after sequencing a panel of genes associated with cataracts, which revealed compound heterozygous SC5D mutations: c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu). The plasma lathosterol concentration was markedly raised at 219.8 µmol/L (control range 0.53-16.0), confirming the diagnosis. The c.630C>A p.(Asp210Glu) mutation has been reported in one previous patient, who also had a relatively mild phenotype (Ho et al., JIMD Rep 12:129-134, 2014). The mutation leads to a relatively conservative amino acid substitution, consistent with some residual enzyme activity. Our patient's family did not notice any benefit from treatment with simvastatin. In summary, milder patients with lathosterolosis may present with learning difficulties, cataracts and very subtle dysmorphism. The diagnosis will be missed unless plasma sterols are analysed or relevant genes sequenced.

4.
J Hum Genet ; 63(6): 707-716, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29618761

RESUMEN

Seven subunits of the mitochondrial contact site and cristae junction (CJ) organizing system (MICOS) in humans have been recently described in function and structure. QIL1 (also named MIC13) is a small complex that is crucial for the maintenance and assembling of MICOS. A novel mutation of an essential splice site in the C19orf70 gene encoding QIL1 induces severe mitochondrial encephalopathy, hepatopathy and lactate acidosis consistent with psychomotor retardation. In addition, bilateral kidney stones were observed. Disassembly of MICOS complex subunits displays lack of MIC10-MIC26-MIC27-QIL1 subcomplex, resulting in aberrant cristae structure and a loss of cristae junctions and contact sites. In liver and muscle tissue, the activity of the respiratory chain complexes (OXPHOS) was severely impaired. Defects in MICOS complex do not only affect mitochondrial architecture, but also mitochondrial fusion, metabolic signalling, lipid trafficking and cellular electric homeostasis.


Asunto(s)
Genes Letales , Hepatopatías/genética , Proteínas de la Membrana/genética , Mitocondrias/metabolismo , Encefalomiopatías Mitocondriales/genética , Proteínas Mitocondriales/genética , Mutación , Desempeño Psicomotor , Acidosis Láctica/complicaciones , Encéfalo/diagnóstico por imagen , Transporte de Electrón , Resultado Fatal , Femenino , Humanos , Lactante , Recién Nacido , Cálculos Renales/complicaciones , Hígado/metabolismo , Hepatopatías/complicaciones , Hepatopatías/fisiopatología , Imagen por Resonancia Magnética , Encefalomiopatías Mitocondriales/complicaciones , Encefalomiopatías Mitocondriales/diagnóstico por imagen , Encefalomiopatías Mitocondriales/fisiopatología , Músculos/metabolismo , Sistemas de Lectura Abierta , Fosforilación Oxidativa , Sitios de Empalme de ARN
6.
JIMD Rep ; 26: 21-9, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26238249

RESUMEN

Congenital disorders of glycosylation form a rapidly growing group of inherited metabolic diseases. As glycosylation affects proteins all over the organism, a mutation in a single gene leads to a multisystemic disorder. We describe a patient with TMEM165-CDG with facial dysmorphism, nephrotic syndrome, cardiac defects, enlarged cerebral ventricles, feeding problems, and neurological involvement. Having confirmed the diagnosis via prenatal diagnostics, we were able to observe the glycosylation right from birth, finding a pathological pattern already on the first day of life. Within the next few weeks, hypoglycosylation progressed to less sialylated and then also to hypogalactosylated isoforms. On the whole, there has not been much published evidence concerning postnatal glycosylation and its adaptational process. This is the first paper reporting changes in glycosylation patterns over the first postnatal weeks in TMEM165-CDG.

7.
Int J Tuberc Lung Dis ; 19(11): 1271-5, 2015 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-26467577

RESUMEN

The Ebola outbreak that started in late 2013 is by far the largest and most sustained in history. It occurred in a part of the world where pre-existing health systems were already fragile, and these deteriorated further during the epidemic due to a large number of health worker deaths; temporary or permanent closure of health facilities; non-payment of health workers; intrinsic fear of contracting or being stigmatised by Ebola among the population, which negatively influenced health-seeking behaviour; enforced quarantine of Ebola-affected communities, restricting the access of vulnerable individuals to health facilities; and late response by the international community. There are also reports of drug and consumable stockouts due to deficiencies in the procurement and supply chain as a result of overriding Ebola-related priorities. Providing tuberculosis (TB) care and achieving favourable treatment outcomes require a fully functioning health system, accurate patient tracking and high patient adherence to treatment. Furthermore, as Ebola is easily transmitted through body fluids, the use of needles-essential for TB diagnosis and treatment-needs to be avoided during an outbreak. We highlight ways in which a sustained Ebola outbreak could jeopardise TB activities and suggest pre-emptive preventive measures while awaiting operational research evidence.


Asunto(s)
Brotes de Enfermedades , Personal de Salud/psicología , Fiebre Hemorrágica Ebola/epidemiología , Tuberculosis/epidemiología , Personal de Salud/economía , Accesibilidad a los Servicios de Salud , Humanos , Investigación Operativa , Estigma Social , Tuberculosis/prevención & control
8.
J Inherit Metab Dis ; 38(5): 931-40, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25778940

RESUMEN

Congenital disorders of glycosylation (CDG) are a group of hereditary metabolic diseases characterized by abnormal glycosylation of proteins and lipids. Often, multisystem disorders with central nervous system involvement and a large variety of clinical symptoms occur. The main characteristics are developmental delay, seizures, and ataxia. In this paper we report the clinical and biochemical characteristics of a 5-year-old girl with a defective galactosylation of N-glycans, resulting in developmental delay, muscular hypotonia, epileptic seizures, inverted nipples, and visual impairment. Next generation sequencing revealed a de novo mutation (c.797G > T, p.G266V) in the X-chromosomal gene SLC35A2 (solute carrier family 35, UDP-galactose transporter, member A2; MIM 300896). While this mutation was found heterozygous, random X-inactivation of the normal allele will lead to loss of normal SLC35A2 activity in respective cells. The functional relevance of the mutation was demonstrated by complementation of UGT-deficient MDCK-RCA(r) and CHO-Lec8 cells by normal UGT-expression construct but not by the mutant version. The effect of dietary galactose supplementation on glycosylation was investigated, showing a nearly complete normalization of transferrin glycosylation.


Asunto(s)
Trastornos Congénitos de Glicosilación/genética , Trastornos Congénitos de Glicosilación/terapia , Proteínas de Transporte de Monosacáridos/genética , Animales , Células CHO , Preescolar , Cricetinae , Cricetulus , Análisis Mutacional de ADN , Perros , Femenino , Galactosa/uso terapéutico , Humanos , Células de Riñón Canino Madin Darby , Proteínas de Transporte de Monosacáridos/deficiencia , Fenotipo
9.
J Anim Sci ; 92(9): 4108-14, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24987071

RESUMEN

Tail docking of feedlot cattle is a management practice used in some confined, slatted-floor feedlots of the midwestern United States. Justification for tail docking in these management systems is to reduce tail injuries and their sequelae and improve performance, but limited evidence exists to support these claims. The primary objective of this study was to determine the effect of tail docking on performance, carcass traits, and health parameters after tail docking in feedlot cattle raised in slatted-floor feedlots. Three separate trials were performed. Trial 1 consisted of 140 Angus-cross (370-kg) yearling steers that spent 144 to 160 days on feed (DOF). Trial 2 consisted of 137 Angus-cross (255-kg) weaned steers that spent 232 DOF. Trial 3 consisted of 102 Holstein steers (370 kg) that spent 185 to 232 DOF. Cattle were randomly assigned to 1 of 2 treatment groups: docked (DK) or control (CN). All steers received an epidural following surgical preparation of the sacrococcygeal area and postoperative intravenous flunixin meglumine. Approximately two-thirds of the tail of DK calves was removed and an elastrator band was placed near the tail tip for hemostasis. Performance parameters collected included daily gain, final weight, feed intake, and feed efficiency. Carcass data included HCW, subcutaneous fat thickness, LM area, KPH percent, marbling, USDA yield grade, and USDA quality grade. Morbidity, mortality, incidence of lameness, and incidence of tail lesions were recorded. Across all 3 trials, there was no significant effect (P < 0.05) of treatment on performance parameters, carcass traits, or health parameters. In all 3 trials, tail tip injuries occurred in 60 to 76% of undocked (CN) calves, developed while living in the slatted-floor environment, compared to 100% of DK calves, whose injuries were a result of the tail docking procedure. We were unable to identify a performance or significant health advantage to tail docking. However, tail tip injuries still occur in cattle raised in slatted-floor facilities. Because of the animal welfare issues associated with tail docking and tail injuries, we recommend pursuing alternative solutions to reducing the incidence of tail tip injury in feedlot cattle housed in confined slatted-floor facilities.


Asunto(s)
Amputación Quirúrgica/veterinaria , Bienestar del Animal/normas , Bovinos/crecimiento & desarrollo , Vivienda para Animales , Cola (estructura animal)/cirugía , Administración Intravenosa , Animales , Peso Corporal , Clonixina/administración & dosificación , Clonixina/análogos & derivados , Grasa Subcutánea
10.
Gene ; 534(2): 345-51, 2014 Jan 25.
Artículo en Inglés | MEDLINE | ID: mdl-24157261

RESUMEN

Congenital disorders of glycosylation (CDG) are a growing group of inherited metabolic disorders where enzymatic defects in the formation or processing of glycolipids and/or glycoproteins lead to variety of different diseases. The deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase, encoded by the human ortholog of ALG1 from yeast, is known as ALG1-CDG (CDG-Ik). The phenotypical, molecular and biochemical analysis of a severely affected ALG1-CDG patient is the focus of this paper. The patient's main symptoms were feeding problems and diarrhea, profound hypoproteinemia with massive ascites, muscular hypertonia, seizures refractory to treatment, recurrent episodes of apnoea, cardiac and hepatic involvement and coagulation anomalies. Compound heterozygosity for the mutations c.1145T>C (M382T) and c.1312C>T (R438W) was detected in the patient's ALG1-coding sequence. In contrast to a previously reported speculation on R438W we confirmed both mutations as disease-causing in ALG1-CDG.


Asunto(s)
Trastornos Congénitos de Glicosilación/genética , Manosiltransferasas/genética , Mutación , Secuencia de Aminoácidos , Resultado Fatal , Glicosilación , Humanos , Lactante , Masculino , Datos de Secuencia Molecular , Alineación de Secuencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA